Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid

Feng, Suying; Wu, Qinxue; Jin, Peng; Lin, Lin; Zhou, Wu-qing; Sang, Honggui; Shao, Changgeng

doi:10.1111/j.1365-4632.2008.03473.x

Cited by 57 publications

(59 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…All but seven patients (4.89%) with mild diseases required systemic therapy. Specific data about the number of patients on different systemic and/or topical treatments was not available for two reports (17,24). All patients clinically improved with the treatment(s) they received (12,16,17,(19)(20)(21)(22)(23)(24).…”

Section: Resultsmentioning

confidence: 92%

See 1 more Smart Citation

Serological Studies in Bullous Pemphigoid: A Literature Review of Antibody Titers at Presentation and in Clinical Remission

Leuci

Gürcan²,

Ahmed³

2010

Acta Derm Venerol

View full text Add to dashboard Cite

Bullous pemphigoid is associated with antibodies to a 230 kDa and a 180 kDa protein. In a literature review we investigated the role of auto-antibodies as detected by different serological assays. Nine reports containing data on 143 patients were analyzed. Pre-treatment data showed that indirect immunofluorescence, enzyme-linked immunosorbent assay (ELISA) and immunoblotting offer an 82.2% or greater probability of being positive. At the end of the study period, all patients had clinically improved, whether or not they were on therapy. Auto-antibodies were present in 29% of patients evaluated by monkey esophagus immunofluorescence and 75% of those evaluated by human skin immunofluorescence. Positive titers were also reported in 67.6% of patients evaluated by ELISA. In 100% of patients in whom immunoblotting was performed the titers became negative. In 3 patients (5.3%) using human skin immunofluorescence and in one patient (1.4%) using ELISA the titers were increased at the end of the study period. The correlation between anti-basement membrane zone antibodies and the clinical course of bullous pemphigoid requires further and long-term studies.

show abstract

Section: Resultsmentioning

confidence: 92%

“…Nine reports, which contained data on 143 patients (12,16,17,(19)(20)(21)(22)(23)(24), published between August 1977 and February 2009, were included in this analysis. However, 51 studies were excluded because they lacked the inclusion criteria set out below.…”

Section: Materials Atsld Methodsmentioning

confidence: 99%

Serological Studies in Bullous Pemphigoid: A Literature Review of Antibody Titers at Presentation and in Clinical Remission

Leuci

Gürcan²,

Ahmed³

2010

Acta Derm Venerol

View full text Add to dashboard Cite

show abstract

“…In particular, anti-BP180 antibody reactivity is closely associated with BP, as it is detectable with absolute accuracy in almost all patients with BP [5][6][7]. Moreover, serum levels of anti-BP180 antibody correlate with disease activity [8]. Bullous pemphigoid has been associated with various renal lesions, and many studies have found that the severity of skin lesions parallels that of kidney disease.…”

Section: Discussionmentioning

confidence: 98%

Membranous glomerulonephropathy in a patient with bullous pemphigoid

et al. 2016

View full text Add to dashboard Cite

Bullous pemphigoid (BP) is a common autoimmune blistering disease that can be complicated by autoimmune disorders. We describe a patient with BP who developed membranous glomerulonephropathy (MN). Proteinuria decreased during the clinical course as anti-BP180 antibody titers decreased. This finding suggested an association between the pathogenesis of these two diseases in terms of immunological disorders.

show abstract

“…Les marqueurs d'activité de la PB sont cliniques (nombre de nouvelles bulles par jour avec si possible une moyenne sur 3 jours) et biologiques avec le taux d'Ac anti-BP180 (ELISA BP180-NC16A) en cours de traitement et non l'immunofluorescence indirecte [28,29]. Les facteurs prédictifs de rechute dans l'année après l'arrêt du traitement sont le taux élevé d'Ac anti-BP180 et la positivité de l'immunofluorescence directe (IFD) à l'arrêt du traitement [30].…”

Section: éVolution Pronosticunclassified

Pemphigoïde bulleuse

Bénéton-Benhard¹

2010

La Presse Médicale

View full text Add to dashboard Cite

Bullous pemphigoid is the most frequent autoimmune bullous skin disease and affects subjects who are about 80 years old. The risk factors are neurological degenerative diseases, poor Karnovski's status and some drugs (aldactone and neuroleptics). Typically, the disease consists of itching eczematous or urticarial sheets, surmounted by blisters. The blisters heal without scars. Mouth and head are rarely involved. The diagnostic is made by histological examination . It shows a subepidermal blister with some degree of dermal infiltrate with lymphocytes and eosinophils. Direct immunofluorescence reveals a linear pattern of IgG deposition along the basal membrane, which signs the diagnosis. Indirect immunofluorescence detecting anti-basal membrane antibodies is of poor diagnostic value. New tests detecting BPAg 2 antibodies by enzyme-linked immunosorbant assay (ELISA) seems to be good markers for disease activity and prognosis. Recommended treatment is topical corticosteroids (clobetasol propionate cream) for several months. It has been showed to be more effective and less dangerous than oral corticotherapy in severe forms of bullous pemphigoid. Corticosteroid sparing agents like methotrexate or mycophenolate mofetil are sometimes used because of cutaneous or systemic side effect of strong and protracted topical corticosteroid therapy. The management of these patients shall be done by specialized and coordinated staff in order to bring the best care.

show abstract

Serum levels of autoantibodies to BP180 correlate with disease activity in patients with bullous pemphigoid

Abstract: BP180 antibody titers showed a closer correlation than indirect immunofluorescence titers to disease activity. The titer of BP180 antibody may be a useful tool for the evaluation of disease activity and for the assessment of the effectiveness of treatments in BP.

Cited by 57 publications

References 11 publications

Serological Studies in Bullous Pemphigoid: A Literature Review of Antibody Titers at Presentation and in Clinical Remission

Serological Studies in Bullous Pemphigoid: A Literature Review of Antibody Titers at Presentation and in Clinical Remission

Membranous glomerulonephropathy in a patient with bullous pemphigoid

Pemphigoïde bulleuse

Contact Info

Product

Resources

About